BioSpace News Archive

Amyris, Inc. (Nasdaq:AMRS), a leading synthetic biotechnology company with leadership in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that, due to public health and safety concerns related to the COVID-19 pandemic, recommendations and orders fr

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on its business.

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst ® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma Pomalyst is the only oral and first new treatment option for Kaposi sarcoma in more than 20 years 1,2 Approval based on Phase 1/2 open label, single-arm clinical trial in HIV-positive and -negative adult patients with symptomatic Kaposi sarcoma 3 PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol Myers S

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, May 18, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the first quarter of 2020 as well as provide an update on business developments and activities. The company’s press release concerning its first quarter 2020 financial results will be available after 1:00 p.m. Pacific Time on Ma

LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today a worldwide license agreement with Iksuda Therapeutics (“Iksuda”) for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors. Under the terms of the agreement, Iksuda will make an upfront payment of USD 5 million and LCB is eligible to receive development, regulator

65% Complete Response in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Of Patients who Achieved a Complete Response and Underwent an Evaluation at Each Timepoint, 97%, 86% and 85% Remained Disease Free at Six, Nine and 12 Months Following Initiation of Therapy, Respectively Positive Data Continue to Validate UroGen’s Proprietary Technology Platform and Value of Intravesical Therapy Dwell Time

The National Osteoporosis Foundation (NOF), the leading health organization dedicated to preventing osteoporosis and broken bones, is delighted to announce the selection of Claire B. Gill as Chief Executive Officer.

Carisma Therapeutics expands on foundational first-of-its-kind engineered macrophage cell therapy platform study and explores time-reducing isolation-to-infusion pathway

Specialty cancer diagnostics company Precipio, Inc., filed its form 10Q for the period ending March 31st, 2020.

A case study published Thursday in the American Journal of Neuroradiology by physicians from Allegheny General Hospital (AGH) in Pittsburgh provides some of the first angiographic images documenting the rapid progression of acute ischemic stroke in a patient with the novel coronavirus (COVID-19).